We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.
- Authors
Zhong, Xiaoyan; Lai, Dan; Ye, Yun; Yang, Xuping; Yu, Bin; Huang, Yilan
- Abstract
Purpose: To assess the efficacy and safety of empagliflozin (EMPA) as add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM). Methods: We searched PubMed, Embase, Medline, OVID, Cochrane Library and Web of Science. Randomized controlled trials of EMPA as add-on to MET for T2DM were included. Two investigators independently selected studies, extracted data and assessed the risk of bias. A meta-analysis was conducted by using RevMan 5.3 software and Stata 12 software. Results: Seven trials including 4256 patients were analysed. Compared with placebo, two different doses of EMPA significantly reduced glycated haemoglobin (HbA1c) [10 mg: weighted mean difference (WMD) −0.57 %; 95 % confidence interval (CI) −0.65 to −0.49 %, P < 0.00001; 25 mg: WMD −0.65 %; 95 % CI −0.72 to −0.57 %, P < 0.00001]. Compared with active comparators (two sitagliptin, one linagliptin and one glimepiride), 10 mg of EMPA provided a similar reduction in HbA1c [WMD −0.10 %; 95 % CI −0.23 to 0.03 %, P = 0.13], while 25 mg of EMPA provided a significantly greater reduction in HbA1c [WMD −0.13 %; 95 % CI −0.20 to −0.06 %, P = 0.0005]. In addition, EMPA as add-on to MET also had a favourable effect on body weight and blood pressure. The risk of hypoglycaemia in the EMPA group was similar to the placebo group or active comparator group. Conclusions: EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. However, high-quality trials with large samples are still needed in order to confirm their long-term safety.
- Subjects
COMBINATION drug therapy; GLYCEMIC index; MEDICAL databases; INFORMATION storage &; retrieval systems; MEDLINE; META-analysis; TYPE 2 diabetes; ONLINE information services; PROBABILITY theory; SYSTEMATIC reviews; TREATMENT effectiveness; METFORMIN; DATA analysis software; EMPAGLIFLOZIN; PHARMACODYNAMICS
- Publication
European Journal of Clinical Pharmacology, 2016, Vol 72, Issue 6, p655
- ISSN
0031-6970
- Publication type
Article
- DOI
10.1007/s00228-016-2010-8